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Condensed abstract: In this randomized, video-vignette study involving 105 Japanese women with 
breast cancer, participants showed significantly lower uncertainty and higher satisfaction without 
increasing anxiety after viewing the video with more vs. less explicit disclosure. When asked about the 
prognosis by Asian cancer patients, clinicians may be encouraged to respect their wishes and explicitly 







Non-disclosure of a poor prognosis to advanced cancer patients remains a typical practice in Asia. 
Although the importance of prognostic communication has increasingly been recognized worldwide, little 
is known about whether explicit prognostic disclosure positively affects Asian patients with advanced 
cancer. We aimed to examine the effects of explicit prognostic communication on patients with cancer 
recurrence. 
Methods 
In this randomized, video-vignette study, Japanese women with breast cancer who had undergone 
curative surgery viewed videos of prognostic communication between a patient with recurrent incurable 
breast cancer and her oncologist. The videos differed only in the presence/absence of explicit prognostic 
disclosure. The primary outcome was participants’ uncertainty (0–10), and the secondary outcomes 
included anxiety (State-Trait Anxiety Inventory (STAI)-State (20–80)), satisfaction (Patient Satisfaction 
Questionnaire (0–10)), self-efficacy (0–10), and willingness to discuss advance care planning (ACP) (1–
4). 
Results 
In total, 105 women participated (age=53.8±8.2). After viewing the video with more vs. less explicit 
disclosure, participants showed significantly lower uncertainty (5.3[SE, 0.2] vs. 5.7[0.2], respectively, 
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p=0.032) and higher satisfaction (5.6[0.2] vs. 5.2[0.2], respectively, p=0.010) without increasing anxiety 
(changes in STAI-State, 0.06[0.5] vs. 0.6[0.5], respectively, p=0.198). No significant differences were 
observed in self-efficacy (5.2[0.2] vs. 5.0[0.2], respectively, p=0.277) or willingness to discuss ACP 
(2.7[0.1] vs. 2.7[0.1], respectively, p=0.240).  
Conclusions 
Explicit prognostic disclosure prompted better outcomes than non-disclosure in Japanese women with 
breast cancer. When asked about the prognosis by Asian cancer patients, clinicians may be encouraged to 
respect their wishes and explicitly discuss the prognosis if deemed appropriate. 
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Explicit prognostic disclosure to advanced cancer patients is considered important, as it can 
reduce uncertainty about the future, and enable them to engage in realistic decision-making and receive 
goal-concordant care 1, 2. Literature from Western countries has demonstrated that the majority of 
advanced cancer patients prefer prognostic communication with their oncologists, and that approximately 
70% of oncologists would disclose the prognosis at the time of diagnosing metastatic cancer 2-5. 
Furthermore, advanced cancer patients who had been told the prognosis had a more realistic prognostic 
estimation and accurate illness understanding than those who had not been told, without worsening 
anxiety or adversely affecting the physician-patient relationship 2, 6. Several guidelines from Western 
countries strongly recommend that physicians provide prognostic information that is tailored to the 
patient’s needs and coping styles to facilitate advance care planning (ACP) 7-9.  
Like Western countries, the importance of self-determination has increasingly been recognized 
in several Asian countries; nowadays, most Asian patients are told of the diagnosis of cancer, and ACP is 
promoted at a national level 10-12. However, disclosure of a poor prognosis is not common in 
communication with advanced cancer patients of Asian origin, as non-disclosure of bad news and a 
family-centered decision-making style remain typical practices in Asian culture 12-15. For example, 
previous surveys in East Asia showed that most physicians would not discuss EOL issues including a 
poor prognosis with advanced cancer patients 14, 15. Other surveys also revealed that up to 40–50% of 
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Japanese and Japanese-American people either did not want to discuss the prognosis at all or preferred 
some level of negotiation with the physician 16-18. Likewise, non-disclosure of a poor prognosis was 
shown to be favored among Chinese migrant cancer patients and their families in Australia 12. Without 
prognostic information, however, advanced cancer patients may suffer marked uncertainty 1. Uncertainty 
is the inability to determine the meaning of illness-related events, especially ambiguity and 
unpredictability of future medical conditions (e.g., treatment effects, rate of disease progression, and their 
impact on the prognosis) 19-21. Furthermore, uncertainty has been shown to correlate with more marked 
symptoms, anxiety and psychological distress, and a negative attitude toward health care 22-24.  
Thus, whether explicit prognostic disclosure has positive effects and recent guidelines from 
Western countries are applicable on communicating with advanced cancer patients with an Asian origin 
must be examined. The primary aim of this study was to examine the effect of explicit prognostic 
disclosure on uncertainty at the time of cancer recurrence in Japan. We also explored whether explicit 
prognostic disclosure improves patient satisfaction without worsening anxiety, and whether it improves 
patient self-efficacy and willingness to discuss ACP.  
 
METHODS 
This is the primary report of a randomized, crossover, scripted video-vignette study that aimed 
to examine the effects of explicit prognostic disclosure. Video-vignettes have been widely utilized to 
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elucidate optimal communication skills in clinical settings of end-of-life discussions on such topics as a 
poor prognosis, the cessation of life-prolonging treatment, and code status 1, 25-28. For the entire study, we 
used an experimental 2 x 2 design to investigate verbal communication elements (i.e., explicitness) as well 
as non-verbal ones (i.e., eye contact). The primary analysis was determined a prior to investigate the effects 
of explicitness (more versus less) on uncertainty in Japan, and the effects of the non-verbal components 
will be reported separately as a secondary analysis. Although this study applied the similar design to that 
of the previous study in the Netherlands, ours is unique in that the effect of explicit prognostic disclosure 
was tested for the first time in the Eastern culture where such disclosure is not common. The study of van 
Vliet, et al. was conducted in the Netherlands and included no participants from an Asian background but 
almost completely participants with a Western European background 1. Also, the patient and oncologist 
depicted in the vide were of Caucasian background 1. The ethical and scientific validity of the study was 
verified by the institutional review board at the National Cancer Center in Japan.  
 
Participants 
Women with breast cancer who were seen in outpatient clinics in the Departments of Breast 
Surgery and Breast and Medical Oncology at National Cancer Center Hospital were recruited from 
August 2016 to March 2017. The inclusion criteria were women who: 1) were aged 20 or older; 2) had 
invasive breast cancer; 3) did not have breast cancer recurrence, and were receiving adjuvant targeted 
9 
 
therapy and/or hormone therapy, or had completed adjuvant chemotherapy, targeted therapy, and/or 
hormone therapy; 4) had undergone breast cancer surgery more than one year before enrollment; and 5) 
had been informed of their cancer diagnosis. Women were excluded if they: 1) had severe cognitive 
impairment; 2) could not read or write Japanese; 3) had difficulty in using a touch panel; 4) were actively 
receiving chemotherapy for breast cancer or other cancers; 5) participated in another intervention study; 





Based on the previous study 1 and following the recommended steps for creating experimental 
video-vignettes 29, 30, four scripted video-vignettes were developed in which an oncologist discussed the 
prognosis with a female patient who was just diagnosed with breast cancer recurrence and metastatic disease. 
These video-vignettes were identical in content, length (5 minutes 10 seconds ± less than 10 seconds), and 
communication, but the “explicitness of the prognosis” varied systematically between the vignettes (more 
vs. less; Appendix). The scripts and manipulations were developed based on a previous study 1. An 
introductory video (2 minutes) was developed in which the video-patient introduced herself and expressed 
her feelings about the upcoming consultation, which aimed to increase participants’ emotional involvement. 
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To ensure the scripts’ internal/external validity, both lay people (breast cancer survivors, healthy women) 
and experts (oncologists, palliative care physicians, and communication experts) were involved in creating 
the written and role-playing scripts, and confirmed their life-like nature, contents, and the manipulation 
success. Clinicians role-played using the scripts to convey a sense of realism, and the videos were filmed 
and edited by a professional company.  
 
Procedure and data collection 
 Each participant was separately invited to a dedicated, quiet study room. After informed 
consent was obtained, their background characteristics were assessed. The order of the presentation of the 
four videos was randomly allocated in advance. The detailed procedure of random allocation was not 
disclosed to the researchers. All participants watched all four videos in a random order (24 patterns of 
order (4x3x2x1)). They were then asked to identify with the video-patient. First, they watched the 
introduction video and the first part of the consultation regarding her cancer recurrence. Then, they 
watched the four different videos. Anxiety was assessed before each video and all outcome measures 
were assessed after each video. A distraction task was provided between the videos (looking at an 
aquarium while listening to background classical music). The validity of this approach has been 




Primary outcome measure 
 Uncertainty (0 – 10, self-rated numerical rating scale (NRS), ranging from 0=very certain to 
10=very uncertain) was the primary outcome measure 1. We applied an NRS rather than a visual analog 
scale (0 – 100) which has previously been used 1, as the former was considered more familiar and easily 
understandable to Japanese patients. We asked the participants to do the following: “please indicate the 
extent to which the manner of the doctor’s communication has made you uncertain about your future”. This 
request was developed based on a previous study 1, and it underwent a formal forward-back translation 
process including the principal investigator of the previous study as well as cognitive testing with breast 
cancer survivors.  
 
Secondary outcome measures 
 Secondary outcome measures were anxiety (State-Trait Anxiety Inventory (STAI)-State), 
satisfaction (Patient Satisfaction Questionnaire (PSQ)), self-efficacy, and willingness to discuss ACP. The 
STAI State consists of 20 items with responses on a 4-point Likert scale, with a higher score indicating 
more marked anxiety 33. The validity and reliability of the Japanese version have been previously confirmed 
34. We used the difference between STAI-State scores before and after each video. The PSQ measures 
participants’ level of satisfaction about communication with a physician measured on 5 items (reliability, 
0.90) 1, 35. The response was rated on an NRS (0 – 10) with a higher score indicating a higher level of 
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satisfaction, and the mean scores of the 5 items were calculated. We performed a formal forward-backward 
translation. Self-efficacy was rated on an NRS (0 – 10), ranging from a very weak to very strong belief in 
the ability to deal with the future 1. Lastly, we rated participants’ willingness to discuss ACP including life-
sustaining treatment and the preferred place of death such as hospice/inpatient palliative care unit with their 
oncologist on a 4-point Likert-type scale (1=very unwilling to 4=very willing) 3, 15, 36. 
 The success of the manipulation—how explicit the prognostic information was perceived as 
being—was measured using a 10-point scale (“not at all” to “very”) 1. 
 
Background measures  
 We measured the following characteristics: demographic variables, physical/psychological 
symptoms (physical and emotional symptom scores of the Edmonton Symptom Assessment System-
revised, Japanese version (ESAS-r-J) 37, 38), preferences for prognostic disclosure (‘not to discuss at all’, 
‘physician to inform me only if I ask’, ‘physician to check with me first whether I want to know’, or 
‘physician to initiate a discussion and inform me in detail’) 16, 18, coping styles (Coping Inventory for 
Stressful Situations (CISS) 39, 40), and whether participants had experiences with loved ones receiving a 
life-limiting cancer diagnosis (“similar experiences” 1) , as they could influence the level of uncertainty 1, 
19, 22-24, 41, 42. The CISS is a 48-item instrument that distinguishes three basic coping strategies with 16 
items per scale: task-oriented, emotion-oriented, and avoidance. The score of each item ranges from 
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1=not at all to 5=very much, and scores for all items per scale are summed to form scale scores, with a 
higher score signifying a greater use of that particular coping strategy. With regards to ESAS-r-J, scores 
of physical (pain, tiredness, drowsiness, nausea, lack of appetite, and shortness of breath) and emotional 
(depression and anxiety) items were summed to form ESAS-physical (0 – 60) and ESAS-emotional (0 – 
20) scores, respectively, with a higher score indicating a greater symptom intensity 38. 
 
Statistical analyses  
We applied the general linear model for the evaluation of a 2×2 intervention of the 
presence/absence of explicit prognostic disclosure and that of eye contact. The score of uncertainty was 
used as the response variable, and more/less explicitness of prognostic disclosure, that of eye contact, those 
interactions, and time were included as explanatory variables in the primary analysis. Robust variance was 
used with consideration of intra-subject correlations of the scores. We estimated the average value of each 
score with and without both interventions (the four videos) and tested the differences in the mean values 
for each intervention. The main concern was the main effect of explicit prognostic disclosure. Multivariate 
regression analyses were used to explore the association between the outcome measures and background 
factors. We combined the data on the effects of eye contact (more vs. less) within each group, as no 





With reference to a previous study by van Vliet et al. 1, we estimated that the difference in the 
mean uncertainty score (primary outcome measure) between the more/less explicitness of prognostic 
disclosure was 0.8 points, the standard deviation of score 1, and the magnitude of the intra-patient 
correlation was 0.2. With a significance level of the test in the primary analysis of 5% (two-sided) and a 
power of 80%, 22 patients would be needed; thus, we set the sample size at 24 in consideration of patient 
dropout, etc. To control for the order effect of a 2×2 intervention, 24×2×2=96 subjects would be needed, 
and 105 subjects were targeted for conclusion. 
We conducted a pilot test with 8 eligible women, examined the mean scores of the primary 
outcome (more explicit disclosure: mean of uncertainty, 4.8; less explicit disclosure: mean, 5.4), and 
confirmed the appropriateness of this sample size calculation before initiating the official patient enrollment. 




Of the 219 women with breast cancer who were approached, 105 (48%) consented and 
participated, 1 withdrew her consent, 3 did not show up to give consent on a scheduled day, and 110 
declined. The reasons for the decline included the lack of time (n=92), psychological burden (n=9), no 
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interest (n=1), and other (n=8) (Figure 1). The participants’ mean age was 53.8. Baseline characteristics 
of the participants are summarized in Table 1.  
 
Manipulation check 
The manipulations succeeded. In the more explicit videos, the prognosis was evaluated as 
being more explicit than in the less explicit videos (more explicit disclosure: mean, 5.7; standard error 
(SE), 0.2; less explicit disclosure: mean, 4.8; SE, 0.2; p<0.001). 
 
Effects of the videos 
After viewing the videos with more vs. less explicit disclosure, participants exhibited 
significantly lower uncertainty (5.3[SE, 0.2] vs. 5.7[0.2], respectively, p=0.032) (bivariate analyses, Table 
2). They also exhibited higher satisfaction after viewing the video with more explicit disclosure (5.6[0.2] 
vs. 5.2[0.2], respectively, p=0.010). No significant differences were observed in changes in STAI-State 
scores (0.06[0.5] vs. 0.6[0.5], respectively, p=0.198), self-efficacy (5.2[0.2] vs. 5.0[0.2], respectively, 
p=0.277) or willingness to discuss ACP (2.7[0.1] vs. 2.7[0.1], respectively, p=0.240) after viewing the 
videos with more vs. less explicit disclosure. 
 
Factors contributing to the uncertainty 
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Multivariate regression analyses (Table 3) revealed that a higher ESAS-Emotional score was a 
significant and independent determinant of a lower uncertainty (β=-0.12, p=0.013) and stronger 
willingness to discuss ACP (β=0.05, p=0.009). In addition, a higher CISS Emotion-oriented score was a 
significant and independent determinant of a higher uncertainty (β=0.05, p<0.001) and lower satisfaction 
(β=-0.04, p=0.008), self-efficacy (β=-0.04, p=0.004), and willingness to discuss ACP (β=-0.03, p<0.001). 
An order effect was also noted with respect to uncertainty: the first (β=1.42, p<0.0001) and second 
(β=0.70, p=0.049) videos as compared with the fourth one were independent determinants of a higher 
uncertainty after viewing the videos. 
 
DISCUSSION 
To the best of our knowledge, this is the first empirical study to demonstrate the effects of explicit 
prognostic disclosure on cancer patients with an Asian origin. The first and most important finding is that 
explicit prognostic disclosure significantly reduced uncertainty and increased satisfaction without causing 
increased anxiety in Japanese women with breast cancer. These findings are consistent with previous studies 
in Western countries 1, 2, and add a new insight into the impact of explicit prognostic disclosure on patients 
from Asian countries. Traditionally, non-disclosure of bad news including a poor prognosis to a patient has 
been common practice, and the role of the family in liaising between clinicians and the patient has been 
emphasized in Asian culture 12-14. Even within a single ethnic population, such as the Japanese, people 
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living in Japan are less likely to value knowing what to expect about one’s condition in the future and more 
likely to value leaving the decision to a medical expert than Japanese-Americans 18. With regard to 
prognostic disclosure in an incurable cancer setting, those living in Japan are more likely to prefer no 
disclosure at all than Japanese-Americans 18. However, generalizations, such as an Asian culture, could lead 
to stereotyping. Especially in this globalization era, the traditional cultural norm should not prevent 
clinicians from exploring individual preferences and information needs. Our findings suggest that while the 
amount of prognostic disclosure should still be tailored to patients’ preferences, explicit disclosure might 
have an overall positive impact on Japanese patients when they ask their physicians about their prognosis, 
and may reassure physicians that the disclosure itself does not necessarily cause anxiety.  
 The second important finding is that several factors were shown to contribute to patient 
outcomes. Order effects have repeatedly been demonstrated in previous video-vignette studies in which 
earlier videos led to more negative outcomes 25, 28. Factors that were significantly correlated with more 
than one outcome included ESAS-Emotional score and emotion-oriented coping. While the prior 
literature indicated that marked physical symptoms were associated with lower uncertainty 41, little is 
known about whether emotional distress could lead to lower uncertainty. As the overall intensities of 
physical and emotional symptoms were low in our patients, these findings may indicate that modest levels 
of anxiety and depression in patients should not preclude prognostic communication if deemed necessary. 
Furthermore, emotion-oriented coping consistently led to negative outcomes after prognostic disclosure. 
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To the best of our knowledge, no study has explored such an association. However, emotion-oriented 
coping has been reported as a maladaptive coping style 43-46, and a prior study of gynecological patients 
undergoing surgery suggested that emotion-oriented coping led to a significantly more severe 
perioperative emotional status 47. These findings suggest that clinicians should provide extra support 
when communicating prognoses to patients who tend to exhibit emotional responses to stressful situations 
(e.g., get angry, become tense, blame themselves for being too emotional). The multivariate analyses 
(Table 3) were explanatory, and their purpose was to explore potential factors other than explicitness 
which could influence uncertainty. Our main concern of this study was the main effect of explicit 
prognostic disclosure on uncertainty. To confirm its effect, we had utilized a randomized controlled 
design, and estimated the sample size based on the binary analysis, which was specified as primary 
analysis in the protocol. Thus, the result of the binary analysis shown in Table 2 is the most important and 
valid. The multivariate analyses also indicated that explicitness tended to be associated with lower 
uncertainty, which is in line with the main analysis.  
Of note, though explicit prognostic disclosure tended to improve self-efficacy, the difference did 
not reach significance, unlike in a previous study 1. Furthermore, explicit disclosure did not improve the 
willingness to discuss ACP. Cultural differences may have contributed to these negative findings. Unlike 
Western culture that values individualism, independence, and autonomy as individual, Asian people 
generally value collectivism, interdependency, and autonomy as a family, resulting in a more family-
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centered decision-making process 48-51. Thus, patients in Asia may find it challenging to develop self-
efficacy in their ability to deal with the future and willingness to discuss ACP without having discussions 
with their loved ones. In addition, improvement of self-efficacy and willingness for discussion is a part of 
the complex process of ACP 52. Future studies are needed to elucidate the longitudinal effects of prognostic 
disclosure combined with multifaceted ACP interventions involving not only patients but also their loved 
ones with an Asian origin. 
Despite the strengths of a randomized design, our study has several limitations. First, we 
conducted an experimental study with women with breast cancer following curative surgery. A previous 
systematic review showed the validity of a randomized scripted video-vignette study 31. However, our 
subjects were patients that were well at the time of study participation, although potentially at risk of 
recurrence in the future. Thus, the emotional reactions of patients with metastatic disease might be more 
intense in actual situations. Second, we recruited relatively young participants at a single cancer center in 
the Tokyo metropolitan area. They may have been more open to explicit discussion, and thus one should 
exercise caution when generalizing our findings to older women or those living in rural areas in Japan, as 
well as those in other Asian countries or to Asian patients in Western countries with various levels of 
acculturation 18. Third, the video-vignette patient asked for explicit prognostic information. Whether the 
same results would be generated if this was not the case remains to be determined. Fourth, we did not pre-
determine the threshold for clinically meaningful difference with regard to the primary endpoint. To the 
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best of our knowledge, there is no current consensus or guideline of a clinically meaningful difference. 
Thus, the statistically significant between-group difference in uncertainty might not fully represent 
clinically important difference. Lastly, experimental designs inherently reduce the complexity of clinical 
interactions, which underlines the importance of future prospective studies in a real-world setting.  
In conclusion, explicit prognostic disclosure led to better outcomes than non-disclosure in 
Japanese women with breast cancer. When cancer patients with an Asian origin ask about the prognosis, 
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Table 1. Baseline characteristics of participants 
 
Characteristics  No. % Mean SD 
Age    53.8 8.2 
Sex, female 105 100   
Marital status 
 Married  






















ER or PgR-positive, HER2-negative 
ER or PgR-positive, HER2-positive 
ER and PgR-negative, HER2-negative 













 Surgery (years ago) 
    (Range, years) 
 
 Radiation therapy, Yes (%)  
  Cancer drug therapy  
Hormone therapy 
Chemotherapy 


























  0 
  1 











Low/medium (<high school/vocational education) 



















20,000 – 40,000 
40,000 – 60,000 











  Paid job 









  Lives with children≤20 years of age, Yes (%) 








Family/close friends who died of advanced cancer, Yes (%) 56 53   
Symptoms (ESAS-r-J) 
 Physical score 
  Emotional score 






Preferences for prognostic disclosure 
Not to discuss at all 
Physician to inform me only if I ask 
Physician to check with me first whether I want to know 

























The ESAS physical score (0-60) represents the sum of ESAS pain/tiredness/drowsiness/nausea/lack of 
appetite/shortness of breath. The ESAS emotional score (0-20) represents the sum of ESAS 
depression/anxiety. 
Abbreviations: SD, standard deviation; ER, estrogen receptor; PgR, progesterone receptor; HER2, human 
epidermal growth factor receptor-related 2; ECOG PS, Eastern Cooperative Oncology Group Performance 
Status; ESAS-r-J, Edmonton Symptom Assessment System revised, Japanese version; CISS, Coping 





Table 2. Main effects of explicit prognostic disclosure on outcomes 
 
 Explicitness (+) Explicitness (-)   
Effect  Mean SE Mean SE Difference  95% CI p 
Uncertainty a 5.3 0.2 5.7 0.2 0.4 0.04, 0.8 0.032 
Satisfaction a 5.6 0.2 5.2 0.2 -0.4 -0.7, -0.1 0.010 
Anxiety: STAI-
State b 
0.06 0.5 0.6 0.5 0.6 -0.3, 1.4 0.198 
Self-efficacy a 5.2 0.2 5.0 0.2 -0.2 -0.6, 0.2 0.277 
Willingness to 
discuss ACP c  
2.7 0.1 2.7 0.1 -0.1 -0.2, 0.1 0.240 
 
a: Scores range from 0 – 10 (low-high) 
b: Differences in scores (20 – 80, low-high) before and after viewing the video 
c: Score ranges from 1 – 4 (low-high) 
Abbreviations: SE, standard error; CI, confidence interval; STAI, State-Trait Anxiety Inventory; ACP, 
advance care planning. 
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Table 3. Factors contributing to the patient outcomes 
 
 
Uncertainty Anxiety Satisfaction Self-efficacy 
Willingness to discuss 
ACP 
 β SE p β SE p β SE p β SE p β SE p 





-1.19 0.70 0.088 -0.18 0.32 0.579 -0.15 0.37 0.694 0.28 0.13 0.032 
  Second  0.70 0.35 0.049 -1.13 0.73 0.121 -0.09 0.33 0.783 -0.01 0.39 0.979 0.12 0.13 0.335 
  Third  0.12 0.41 0.767 0.42 0.68 0.540 0.04 0.36 0.923 0.19 0.42 0.654 0.06 0.14 0.649 
  Fourth (Ref) 0   0   0   0   0   
Explicitness, no vs. yes (Ref)  0.44 0.25 0.074 0.51 0.69 0.461 -0.41 0.23 0.078 -0.21 0.27 0.432 -0.09 0.10 0.371 
Age -0.00 0.02 0.991 -0.00 0.05 0.962 -0.00 0.02 0.936 0.00 0.02 0.914 -0.00 0.01 0.918 
Marital status, married vs. single (Ref) 0.39 0.29 0.178 -1.50 0.83 0.072 -0.02 0.28 0.950 0.29 0.34 0.393 0.07 0.10 0.460 
Highest education, high vs. low/medium (Ref) 0.46 0.29 0.116 -0.48 0.85 0.578 -0.06 0.27 0.839 -0.33 0.32 0.310 0.04 0.11 0.696 
Subtype                
ER and PgR-negative, HER2-positive 0.93 0.53 0.084 -0.91 1.29 0.483 0.61 0.58 0.291 0.90 0.66 0.178 0.05 0.24 0.839 
ER and PgR-negative, HER2-negative 0.45 0.85 0.600 -0.17 2.93 0.955 -0.79 0.54 0.146 -0.57 0.64 0.370 -0.91 0.34 0.008 
ER or PgR-positive, HER2-positive 0.34 0.37 0.369 1.51 1.12 0.178 0.08 0.32 0.800 -0.14 0.41 0.739 0.07 0.13 0.608 
ER or PgR-positive, HER2-negative (Ref) 0   0   0   0   0   
Treatment history                
Years since surgery 0.05 0.05 0.277 0.02 0.13 0.863 -0.04 0.04 0.365 0.06 0.05 0.208 0.01 0.02 0.554 
  Radiotherapy, yes vs. no (Ref)  0.47 0.31 0.131 -0.37 0.79 0.643 -0.15 0.28 0.598 -0.37 0.34 0.280 -0.20 0.11 0.077 
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  Neoadjuvant and/or adjuvant chemotherapy, 
yes vs. no (Ref) 
-0.08 0.35 0.816 -0.47 0.84 0.574 -0.33 0.35 0.344 -0.29 0.41 0.481 -0.14 0.14 0.303 
ECOG PS 1 – 2 vs. 0 (Ref)  -0.32 0.34 0.351 -0.09 0.87 0.918 0.20 0.28 0.483 -0.06 0.35 0.871 0.15 0.14 0.267 
Stage, II/III vs. I (Ref) -0.39 0.33 0.236 -1.42 0.91 0.118 -0.50 0.30 0.101 -0.70 0.37 0.061 0.08 0.13 0.552 
ESAS-Physical  0.04 0.03 0.177 -0.01 0.08 0.926 -0.00 0.03 0.935 -0.01 0.03 0.716 -0.02 0.01 0.044 
ESAS-Emotional  -0.12 0.05 0.013 0.09 0.13 0.487 0.06 0.04 0.172 0.03 0.05 0.582 0.05 0.02 0.009 
CISS Task-oriented  -0.01 0.02 0.450 0.01 0.04 0.751 -0.01 0.02 0.510 -0.01 0.02 0.647 -0.01 0.01 0.013 




0.09 0.05 0.067 -0.04 0.01 0.008 -0.04 0.02 0.004 -0.03 0.01 
<0.00
1 
CISS Avoidance  -0.03 0.01 0.062 -0.07 0.04 0.068 0.02 0.01 0.215 0.02 0.02 0.142 0.01 0.01 0.123 
Family or close friends who died of advanced 
cancer, yes vs. no (Ref)  
0.34 0.28 0.230 -0.10 0.80 0.897 0.11 0.25 0.655 0.01 0.30 0.981 0.26 0.11 0.017 
Preferences for prognostic disclosure, 
disclosure with or without negotiation vs. no 
disclosure (Ref) 
-0.01 0.29 0.981 -0.34 0.80 0.670 -0.25 0.25 0.329 -0.26 0.30 0.378 0.36 0.11 0.002 
 
High education indicates “university and graduate school”, and low/medium “less than high school and vocational education”. The ESAS physical score (0-60) 
represents the sum of ESAS pain/tiredness/drowsiness/nausea/lack of appetite/shortness of breath. The ESAS emotional score (0-20) represents the sum of ESAS 
depression/anxiety. 
Significant values (p<0.05) are in bold. 
Abbreviations: ACP, advance care planning; SE, standard error; Ref, reference; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth 
factor receptor-related 2; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ESAS, Edmonton Symptom Assessment System; CISS, Coping 




Figure 1. CONSORT diagram 





Appendix 1. Final scripts including manipulations 
 











Overview shot of patient/husband and oncologist 
Shot oncologist  
Shot patient/husband 
Total shot 
Middle close up 








P: My name is Kazue Saito, I’m 45 years old. I live with my husband and two children; a 17-year-old girl 
and a 15-year-old boy. Two years ago I was diagnosed with breast cancer. I’ve had breast-conserving surgery 
to remove the tumor. To be on the safe side, I first received radiation therapy and afterwards chemotherapy 
to kill cells that may still be there but which cannot be seen. After a while, my life seemed to get back on 
track again. However, one month ago I felt a lump in the same breast. Of course, I was in shock and 
immediately called the hospital. I got an appointment with the surgeon right away. He did a physical exam 
and felt my lymph nodes. He didn’t have a good feeling about it all, so last week I had a bone scan and CT 
P＋H are sitting in a waiting room. 
P talks. She looks anxious and nervous. From 
time to time, she stares and looks restlessly 
around her. She fiddles with her hands/fingers.  
Voice falters somewhat. 
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of my liver and lungs to see if the cancer has come back. I can’t believe it. But I have an appointment with 





O: Hello Mr. and Mrs. Saito, my name is Dr. Suzuki. Please have a seat. CAM1/T O opens the door and bows. 
P+H are sitting down, next to each other, facing O, 
who has also taken a seat.  
O: So, you went to see the surgeon, Dr. Tanaka, after you felt a lump in your breast. Doctor Tanaka did an 
exam and suspected that the cancer might have recurred. Therefore, a puncture of a lymph node near 
the collarbone was done and both a bone scan and CT of your liver and lungs were conducted.  
CAM3/M O talks calmly and looks at P＋H. 
P: Yes, that’s correct. That all happened last week.  CAM2/M P makes eye-contact and looks away.  
O: Yes, it all happened last week. I have the test results of the examinations. Unfortunately, I do not have 
good news for you. We have found metastases in the lymph node near the collarbone and the liver and 
bones.  
CAM3/M O nods. Puts the patient charts in front 
of him. CAM2/C O talks slowly, showing imaging 
on the electronic medical record. 
 P looks straight ahead.  
1 second of silence. 
P: Oh no. P stares blankly ahead. 
H: (H doesn’t say anything as if to express the unbelievable nature of the news) P looks down, and looks to H for a short duration. 
P: Well…this does mean that you can’t remove it, right?  Question is posed in a soft voice, but with eye-
contact, though P looks downward.  
O: With these kind of metastases, it is no longer possible to remove the cancer completely and cure you. CAM3/M O is leaning forwards slightly. 
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However, I do not want to portray things better than they are.  O looks at P and H in a serious and calm manner.  
P:  I still feel fine… I can’t die. Especially for the kids!  CAM2/C P braces herself somewhat and leans 
forward.  
O: Yes, that makes it more difficult to grasp doesn’t it? P looks forward. 
P: Yes, but how bad is it?  She does pose the question firmly and with eye-
contact.  
O: What do you mean exactly? CAM3/M O hesitates for a moment. 
[EC+] O leans forwards. 
[EC-] O moves his head slightly toward P 
 
Prognosis sequence – less explicitness 
Verbal Non-verbal 
P: How long have I got? CAM2/M   
O: Your life-expectancy? CAM3/C O sounds a bit uncomfortable/asks for 
confirmation. 
P: Yes, as a rough idea. I would like to know for my kids. Do you know that in general terms? CAM2/M P looks at O in a firm yet slightly 
anxious way. 
O: That’s very difficult to predict, because it can differ from person to person and depend on future 
treatment and your stamina. So no one knows your life-expectancy. You do have a very serious disease, 
which will limit your life expectancy. That is the only thing we can say for sure. There are women who 
live for quite a long time with the type of cancer you have, and there are women who live for a shorter 
time. The comments you often see on television or read in magazines, about ‘you only have so long to 
live’, aren’t realistic, because we do not know that in any individual case… So, no, I don’t know how 
it will be for you.  
CAM3/C O nods his head to show his 
understanding, and starts to talk in a serious way.  
P: Yes, I understand that. That’s something you can’t predict.   




Prognosis sequence – more explicitness 
Verbal Non-verbal 
P: How long have I got? CAM2/M   
O: Your life-expectancy? CAM3/C O sounds a bit uncomfortable/asks for 
confirmation. 
P: Yes, as a rough idea. I would like to know for my kids. Do you know that in general terms? CAM2/M P looks at O in a firm yet slightly 
anxious way. 
O: That’s very difficult. But I can give you some concrete numbers and averages. Would you like me to 
discuss these with you?  
CAM3/C O nods his head to show his 
understanding, and starts to talk in a serious way. 
P: Yes.  
O: When we look at what is known from studies of patients with your type of cancer cells and metastases, 
50% of the patients are still alive after 2 years. So half the people will live longer than 2 years, while the 
other half will die within 2 years. Some people might live much longer, maybe as much as 4 years, but others 
might only live for half a year.  
 
P: Yes…, I understand that. So you can’t predict which group I belong to?   





P: And what now?  CAM2/M 
O: Where do we go from here? You have already had radiation and chemo after surgery. Our goal from now 
is to live for as long as possible with your cancer.  
CAM3/C O looks a bit more confident. Leans 
slightly forward.  
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P: But what can you do?  CAM1/T 
O:  Because the cancer has spread and your cancer is not hormone-sensitive, we will treat you with 
chemotherapy rather than an operation or hormone therapy. If you want that, in principle, we will do 
three courses, every 3 weeks. Then we’ll look at how you feel and how burdensome the treatment is, and 
how it goes physically, is it working, which we can see with a scan.  
CAM3/M O leans backwards. O tries to talk 
calmly.  
CAM2/C P looks devastated, anxious.  
 
CAM1/T  
P: So, chemo? CAM3/C 
O: Yes. That is something we do not need to decide immediately though. With chemo we might be able to 
suppress the growth of the tumor. But chemo does cause side-effects.  
O continues to look at P attentively. 
P: Yes… We (looks at H) have to discuss this; together with the family.  
However, I don’t think we have a choice. I have to receive treatment for the children. That means 
everything to me.  
CAM2/C P has her hand in front of her chest.  
P＋H make eye-contact. P has a lump in her throat.  
O: I understand. Therefore, I think that it would be a good idea to discuss in detail all the possibilities during 
our next appointment, if that’s okay with you. Let’s think about what we can do together. (Conversation 
fades away.)  
CAM3/C O looks at P＋H. He tries to temper the 
emotions by continuing the conversation in a 
matter of fact manner.  
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